Replies to post #117724 on Biotech Values

[JJM760]

JQ

At what point would you no longer consider Pona "high" risk? IMO Berger is not selling anytime soon, but that doesn't prevent someone from making a hostile offer.

Thanks

[BTH]

Never said that would buy an oncology company.

Just stating that their oncology division is probably the weakest they have.

[DewDiligence]

There are some exceptions, however, such as ABT-FACT, SNY-BiPar, and JNJ-CGRB.